Exploring the Latest Research and Opportunities in T-reg Therapy

Dr. Qizhi Tang, Professor and Director at the Transplantation Research Lab in the Department of Surgery at UCSF; and Dr. Randall Alfano, Vice President at InVitria, discuss the latest developments in T-reg research and clinical application in these presentations. 

Preview the Introductory Video Below: 

 Worldwide, researchers and industry leaders are improving health outcomes for patients by utilizing the multi-functional efficacy of regulatory t cells to develop novel therapies and disease treatments. Regulatory T cells, commonly referred to as ‘T-regs’, play a critical role in maintaining order in the human immune system by regulating and suppressing excessive inflammation. Given the therapeutic potential of T-regs for patients with autoimmune diseases, cancer, and organ transplants, both researchers and industry leaders are developing novel therapies that utilize the multi-functional efficacy of T-reg cells in disease treatments to improve health outcomes for patients. 

In these presentations, Dr. Qizhi Tang, and Dr. Randall Alfano discuss the latest developments in T-reg research and clinical application. 

  Watch Now  

 

 

Two Exciting Presentations by Leaders in T-reg Therapy!  

Exploring the Latest Research and Manufacturing Challenges in T-reg Therapy

QizhiTangIn this presentation, Dr. Qizhi Tang, Professor and Director at the Transplantation Research Lab in the Department of Surgery at the University of California, San Francisco discusses the latest developments in T-reg research and clinical application. 

The Tang lab focuses on translating knowledge on mechanisms of immune tolerance into novel therapeutics for treating autoimmune disease, diabetes and preventing transplant rejection. Currently, two major areas of her work are focused on the therapeutic application of regulatory T cell therapy in type 1 diabetes and transplant rejection, or GvHD.

In this presentation, she shares the latest research conducted by her lab using T-reg cells for therapy, the benefits of these therapies, and explores the technical challenge of commercializing T-reg therapies that require new approaches in manufacturing and regulatory review. 

  Watch Now   

Ensuring T-reg Cell Therapy Success with Blood Free and Chemically Defined Media

RandallAlfanoInVitria designs and produces the most reliable blood-free and chemically-defined products for use in cell culture, regenerative medicine, CAR-T, gene therapy, cell-based vaccines and tissue preservation. 

Our blood-free cell culture media is used by researchers and industry leaders on a global basis as they improve health outcomes for patients. InVitria’s scientists are designing novel cell culture media products to improve manufacturing of commercial scale regulatory t cells for clinical use.

InVitria products not only provide improved patient safety in comparison to serum, but our custom media formulations give the leaders developing these T-reg therapies more control over their manufacturing system and supply chain, streamlining the regulatory approval process.

In his presentation, Dr. Randall Alfano, Vice President at InVitria will discuss T-reg expansion in chemically defined media without using serum or blood-derived components and why this is critical in the overall success of T-reg therapies. 

  Watch Now  

 

Fill Out This Form To Watch the Presentations: